nav Searchuser
Maxunitech Inc.
Beijing Multigrass Formulation Co., Ltd.

Certis USA in plant disease control technologies licensing agreementqrcode

Dec. 12, 2011

Favorites Print
Dec. 12, 2011
Certis USA has entered into a global license agreement with Montana State University-Bozeman and Montana BioAgriculture Inc. of Missoula, MT to develop and commercialize new plant disease control technologies based on Bacillus mycoides isolate BmJ.

BmJ is a naturally occurring, nonpathogenic bacterium that triggers a plant’s immune response to pathogenic fungi, bacteria and viruses resulting in systemic acquired resistance (SAR) to diseases. BmJ does this by a mechanism very similar to that of chemical SAR activators, but with equal or better disease control for longer periods and with lower risk of phytotoxicity. While some microbial biofungicides have been reported to also have moderate activity as SAR activators, BmJ is unique in that it works entirely as a microbial SAR activator with no direct effect on the plant pathogen itself. These characteristics make BmJ a valuable tool for use in fungicide resistance management programs.

Montana State University (MSU) has patented methods for inducing SAR in plants by applying BmJ-based control agents, and related patents are pending. The technology has been under development by MSU and Montana BioAgriculture, and the collaboration has proven the efficacy of BmJ against Cercospora leaf spot in sugar beets, white mold and early blight in potatoes, and several other crop diseases. Certis USA plans to commercialize this technology worldwide in an expanded range of crops and diseases.

Picture 0/1200

More from AgroNews

Sichuan Lomon Bio Technology Co., Ltd.


2019 India Pesticide Suppliers Guide 2019 Latin America Focus
2019 Formulation & Adjuvant Technology Annual Review 2018
Chinese issue of Annual Review 2018 Chinese issue of 2018 Market Insight
I wanna post a press Comment


Subscribe Email: *
Mobile Number:  


Picture 0/1200

Subscribe to daily email alerts of AgroNews.